Ascendis Pharma A/S - SPONSORED ADR (ASND)

Historical Portfolio Holders from Q1 2015 to Q3 2024

All holders as of June 30, 2024
Q2 2024
Type / Class
Equity / SPONSORED ADR
Shares, excl. options Q2 2024
60.6M
Holdings value Q2 2024
$8.26B
Value change Q2 2024
-$25.2M
Grand Portfolio weight change Q2 2024
0%
Number of holders
199
Number of buys Q2 2024
17
Number of sells Q2 2024
-14
Average buys Q2 2024 %
+0%
Average sells Q2 2024 %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q3 1.52M $225M +$32M $149.31 40
2024 Q2 60.6M $8.26B -$25.2M $136.38 199
2024 Q1 60.7M $9.17B +$191M $151.17 187
2023 Q4 59.4M $7.49B -$100M $125.95 183
2023 Q3 60.3M $5.64B -$61.7M $93.64 161
2023 Q2 61M $5.45B -$42.8M $89.25 161
2023 Q1 61M $6.53B -$604M $107.22 163
2022 Q4 65.9M $8.05B -$68.8M $122.13 184
2022 Q3 66.7M $6.89B +$148M $103.26 177
2022 Q2 63.2M $5.87B +$99.3M $92.96 165
2022 Q1 61.9M $7.27B +$416M $117.36 172
2021 Q4 58.4M $7.85B -$60.4M $134.53 168
2021 Q3 58M $9.24B +$506M $159.39 166
2021 Q2 55M $7.24B +$278M $131.55 170
2021 Q1 52.7M $6.79B -$260M $128.88 173
2020 Q4 54.3M $9.06B +$121M $166.78 174
2020 Q3 53.5M $8.26B +$777M $154.32 151
2020 Q2 48.2M $7.13B +$39M $147.90 150
2020 Q1 47.9M $5.39B +$191M $112.61 143
2019 Q4 46.1M $6.42B -$13.7M $139.12 141
2019 Q3 46.1M $4.44B -$194M $96.32 128
2019 Q2 47.7M $5.49B +$237M $115.15 133
2019 Q1 46M $5.41B +$717M $117.70 140
2018 Q4 40.1M $2.51B -$10.8M $62.65 104
2018 Q3 40.2M $2.85B +$44.5M $70.86 94
2018 Q2 39.6M $2.63B +$96.2M $66.52 100
2018 Q1 38.1M $2.49B +$345M $65.40 89
2017 Q4 30.5M $1.22B +$52.9M $40.06 64
2017 Q3 28.8M $1.04B +$201M $36.25 59
2017 Q2 23.3M $646M +$81.3M $27.76 34
2017 Q1 20.9M $585M +$9.05M $28.00 35
2016 Q4 20.6M $416M +$131M $20.24 30
2016 Q3 14M $281M +$4.79M $20.10 22
2016 Q2 13.9M $184M +$10.2M $13.27 23
2016 Q1 12M $223M +$9.84M $18.55 25
2015 Q4 10.1M $185M +$7.68M $18.32 24
2015 Q3 8.93M $158M -$14.9K $17.70 24
2015 Q2 8.95M $158M +$7.73M $17.68 31
2015 Q1 8.48M $146M +$146M $17.35 36